New obesity pill enters human testing in china
NCT ID NCT07499050
First seen Apr 02, 2026 · Last updated Jun 23, 2026 · Updated 11 times
Summary
This early-stage trial tests an experimental daily pill called RO7795081 in 30 healthy Chinese adults who are overweight or obese. The main goal is to check the drug's safety and how the body handles it, not yet to prove weight loss. Participants will receive either the drug or a placebo for a short time, and researchers will monitor side effects, including mood and suicidal thoughts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nanjing Gulou Hospital
RECRUITINGNanjing, China
-
Ruijin Hospital Shanghai Jiaotong University School of Medicine
RECRUITINGShanghai, 200003, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RO7795081 (also known as CT-996, RG6652) - an experimental oral drug for weight loss
What this could lead to
If successful, this could lead to a new daily pill to help manage weight in people with obesity or overweight.
What could go wrong
This is a very early Phase 1 trial with only 30 participants, so it is primarily checking safety. The drug may not cause significant weight loss or could have side effects like psychiatric issues.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.